Gerosynth Labs, Inc., a private biotechnology company specializing in pharmaceutical preparations for oncology and regenerative health, and parent company of Mytosynth Nutraceuticals, LLC, today announced the launch of Mytulin EQ, a next-generation equine nutritional supplement designed to support immune health, cellular vitality, and performance recovery.Developed through proprietary phytochemical research, Mytulin EQ promotes musculoskeletal strength, gastrointestinal balance, and mitochondrial rejuvenationkey factors in optimizing equine health and longevity.Mytulin EQ represents the culmination of years of translational research at the intersection of biotechnology and animal health, said Alisha ODell, CEO and Founder of Gerosynth Labs. Our goal is to bring evidence-based, naturally derived solutions to market that advance equine wellness without the limitations often associated with traditional pharmaceuticals.The proprietary formulation is derived from wild-harvested chaga mushrooms sustainably sourced from Alaskas Arctic Circle. The extreme climate conditions, combined with Gerosynths breakthrough discovery in manufacturing its formulations, produce a nutrient-dense, bioactive composition, resulting in a potent natural foundation for equine cellular support and performance optimization.Horses performing at a high level demand exceptional cellular recovery and immune resilience, said Kendall Willson, DVM, MRCVS. Mytulin EQs formulation supports both performance and long-term health, giving veterinarians and trainers a valuable new tool for sustained equine wellness.Mytulin EQ is available now at mytosynth.com in single 64 oz. pouches for $280 or three 64 oz. pouches for $540. Throughout the month of November, try it for a discounted introductory price of $220 per single pouch.